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INTRODUCTION 
 Hepatocellular carcinoma (HCC) is a major health burden 
and its incidence is increasing globally.
1
 HCC ranks the 6
th
most 
common cancer worldwide with more than 1 million new cases 
diagnosed every year.
2
 Regardless of etiology, more than 80% of HCC 
occur in patients with cirrhosis worldwide.
3 
However, in India, more 
than 40% of HCC occurs in non-cirrhotic liver.  
The presence or absence of underlying liver disease is important 
because the clinical presentation, treatment approaches and prognosis 
differs depending upon whether HCC develops in cirrhotic or non-
cirrhotic liver.
4
 In patients with HCC in cirrhotic liver, tumors are more 
likely to be detected early as part of routine screening and hence are 
treated by more minor intervention or by liver transplantation. 
Conventional liver resection is rarely performed in patients with HCC in 
cirrhotic livers, owing to the risk of post-hepatectomy liver failure.
5 
In 
contrast, patients with non-cirrhotic liver present at later stage with large 
tumors and are usually treated by major liver resection due to high rate 
of recurrence in transplanted liver.
6,7
 
 Although multiple treatment modalities have been established for 
HCC over the past decades, surgery – liver resection or transplantation - 
gives the best chance of long term survival and cure.
8
 In general, the 
role of liver transplantation for non-cirrhotic patients with HCC is not 
clear because they usually fall outside the current transplantation 
criteria, issue of organ shortage, associated with high rate of recurrence 
in transplanted liver and high mortality rate of up to 25% among patients 
on the transplant wait list. Moreover, transplantation for HCC in non-
cirrhotic liver has no additional benefit of improving the patient’s long 
term liver function.
9
Several studies have shown that hepatic resection 
can offer optimal therapy for non-cirrhotic patients with HCC. However, 
intrahepatic recurrence after curative resection of HCC is unacceptably 
high in non-cirrhotic patients. Therefore, in order to improve the 
surgical outcomes in these patients, it is of paramount importance to 
identify the prognostic factors for survival and the risk factors for intra-
hepatic tumor recurrences after curative resection for HCC in non-
cirrhotic liver.
10
 
The alternative treatment options, such as trans-arterial 
chemoembolization (TACE) and radiofrequency ablation (RFA), are 
limited by lack of complete tumor eradication and are clearly not 
suitable for such large tumors in non-cirrhotic HCC patients. 
The significant improvements in diagnostic imaging, surgical 
techniques and post-operative care have shown very low operative 
mortality in the experienced centers.
11
Despite these advances, the long 
term prognosis of patients with HCC is dismal. Numerous publications 
have addressed the prognostic factors and long term survival after liver 
resection for HCC, but most of these studies have included patients with 
and without cirrhosis.
12-16
 The prognostic factors for survival or the risk 
factors for tumor recurrence in patients undergoing liver resection for 
HCC in non-cirrhotic liver is not well documented.
17
Data analyzing the 
outcomes of liver resection for HCC in patients with non-cirrhotic liver 
is also limited.
4
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AIM OF THE STUDY 
The aim of the present study was:  
1. To compare the clinic-pathological and technical factors between 
patients with HCC in non-cirrhotic, non-fibrotic liver and that in 
cirrhotic liver.  
2. To evaluate the peri-operative and short-term outcomes after liver 
resection for HCC in non-cirrhotic liver. 
3. To identify predictive factors and outcome after liver resection for 
non-cirrhotic HCC. 
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REVIEW OF LITERATURE 
 Hepatocellular Carcinoma (HCC) is the most common primary 
malignant tumor in the adult liver.
18
 HCC is the sixth most common 
cancer with 749,000 new cases per year and accounts for 7% of all new 
cancer diagnosed worldwide.
19
It is a deadly malignancy and the 3
rd
cause 
of cancer related death with 692,000 deaths worldwide per year.
18
 
The global distribution of HCC presents marked geographical 
variation. According to age-adjusted incidence rate (AAIR) per 100,000 
population per annum, the different geographical regions of HCC can be 
divided into three incidence zones: Low (<5), intermediate (between 5 
and 15), high (>15).
20
 Most Asian countries, including India are in the 
intermediate or high incidence zone for HCC.
21
 
 Several registries have shown that the HCC incidence rates have 
changed during the past several years. Hepatitis B virus vaccination and 
improvements in health standards have decreased the incidence rate in 
some high risk areas such as Taiwan and Japan. In contrast, HCC 
incidence is increasing in the United States and India, probably 
reflecting the different timing in the appearance of risk factors.
18
 In 
India, the four population based registries at Chennai, Bangalore, 
Mumbai and Delhi have shown statistically significant increase in 
incidence of liver cancer (Figure 1). The annual percent change (APC) 
was 1.6 for Chennai and Delhi, 2.0 for Bangalore and 2.6 for Mumbai. 
The average incidence of HCC in India is 2.7% for males and 1.3% for 
females.
22,23
 
 
 
 Worldwide, up to 90% of HCC are associated with  
cirrhosis, 
24,25-28
  however in India, up to 40% of HCC occurs in  
non-cirrhotic liver.    
DEMOGRAPHIC CHARACTERISTICS: 
 Most studies regarding non-cirrhotic liver have demonstrated 
equal sex distribution (male/female ratio: 1.3-2: 1) when compared with 
cirrhotic counterpart with male predominance (male/female ratio: 3.2 to 
Figure 1: The incidence of HCC in the four population 
based registries at Chennai, Bangalore, Mumbaiand Delhi 
8:1).
26,27
 The mean age at presentation in non-cirrhotic is about 10 year 
lower thanin cirrhotic patients.
11,29
 
ETIOLOGICAL FACTORS: 
1. Chronic viral hepatitis: 
 Hepatitis B virus (HBV) or C virus (HCV) chronic infections are 
the major risk factors in non-cirrhotic HCC, as seen in cirrhotic patients 
with HCC. Table-1and 2 shows the prevalence of HBV surface antigen 
(HBsAg) positive and anti-HCV antibody positive status in cirrhotic and 
non-cirrhotic patients with HCC coming from different geographical 
areas. 
Table 1: The reported prevalence of HBsAg positive status in non-
cirrhotic and cirrhotic patients with hepatocellular carcinoma (HCC) in 
the literature. 
 
Reference 
             HBsAg positive status 
Non-cirrhotic                   Cirrhotic 
HCC patients (%)   HCC patients (%) 
 
p-value 
Trevisani et al
26
 10/102 (9.8%) 81/360 (22.5%) 0.007 
Nzeako et al
27
 17/342 (5.0%) 43/462 (9.3%) <0.05 
Bralet et al
49
 11/80 (13.7%) 79/250 (31.6%) 0.003 
Shimada et al
29
 7/65 (10.8) 102/450 (22.7%) 0.034 
Grazi et al
11
 17/135 (12.6%) 46/308 (14.9%) n.s 
Chang et al
9
 142/221 (64.3%) 150/217 (69.1%) n.s 
Kumar et al
112
 26/52 (50.0%) 85/137 (62.0%) n.s 
HBsAg: Hepatits B surface antigen, HCC: hepatocellular carcinoma, 
n.s: not statistically significant 
 
Table 2: The reported prevalence of anti-HCV positive status in non-
cirrhotic and cirrhotic patients with hepatocellular carcinoma (HCC) in 
the literature. 
 
Reference 
Anti HCV antibody positive  status 
 
 
p-value 
Non-cirrhotic 
HCC patients (%) 
Cirrhotic 
HCC patients (%) 
Trevisani et al
26
 15/28 (53.6%) 104/138 (75.4%) 0.03 
Bralet et al
49
 2/80 (2.5%) 68/250 (27.0%) 0.0001 
Shimada et al
29
 22/42 (52.4%) 243/332 (73.2%) 0.007 
Grazi et al
11
 33/135 (24.4%) 182/308 (59%) <0.001 
Chang et al
9
 39/216 (18.1%) 57/208 (27.4%) 0.02 
Kumar et al
112
 1/52 (1.9%) 22/137 (16.1%) n.s 
HCV: Hepatitis C virus, HCC: hepatocellular carcinoma, n.s: not 
statistically significant 
 
 HBV can directly cause hepatic carcinogenesis, independent of 
the development of cirrhosis.
30
 This is possible because HBV is a DNA 
virus and hence can integrate into host DNA leading to host DNA 
microdeletions and produce HBx protein that modifies the host growth 
control genes.
18
More recently, many studies have shown that the 
mutations in basal core promoter region, HBeAg seropositivity, HBV 
genotype C and a high viral load (10
4-5
copies/ml) are independent 
predictors of HCC development even in the absence of cirrhosis.
31-33
 
Hence in the future, identification of these factors could be applied to 
predict HCC risk in HBs Ag carriers irrespective of the presence of 
cirrhosis.
24
 
 The main mechanism of HCC development in chronic HCV 
infection is due to sustained viral replication leading to necro-
inflammatory process. This results in high proliferative rate and 
increased risk for DNA mutation. Accumulation of these genetic 
changes over time confers a survival advantage with abnormal 
phenotype. Hence, nearly all HCV related HCC occurs against a 
background of advanced liver fibrosis or cirrhosis.
5,34,35
 However, 
specific HCV gene products (core, NS3, NS4B and NS5A)
36,37
 has 
produced malignant transformation in murine fibroblast culture 
suggesting that HCV also has a direct carcinogenic potential.
38,39,40
 
 The detection of HBV and HCV infections by serology 
underestimates their etiological role because HBV-DNA and HCV-RNA 
fragments have been identified in livertissue and/or serum of 18% to 
33% of patients respectively, in non-cirrhotic HCC individuals with 
negative serological markers.
41
 
2. Alcohol intake: 
 Numerous studies have addressed that fact that heavy alcohol 
intake has been less common in non-cirrhotic HCC patients (Table 3). 
This is in concordantwith the hypothesis that hepato-carcinogenic 
potential of alcohol is almost always due to development of 
cirrhosis.
42.43
 
Table 3: The reported prevalence of alcohol intake in non-cirrhotic and 
cirrhotic patients with hepatocellular carcinoma (HCC) in the literature. 
Reference   Alcohol intake 
Non-cirrhotic                  Cirrhotic 
HCC patients (%)   HCC patients (%) 
 
p-value 
Trevisani et al
26
 15/91 (16.5%) 105/350 (30.0%) 0.01 
Nzeako et al
27
 25/342 (7.3%) 130/462 (28.1%) <0.0001 
Bralet et al
49 
 11/80 (13.7%) 73/250 (29.2%) 0.009 
Shimada et al
29
 44/63 (69.8%) 232/433 (53.6%) 0.022 
Grazi et al
11
 29/135 (21.5%) 67/308 (21.7%) n.s 
Chang et al
9
 98/223 (43.9) 99/222 (44.6%) n.s 
Kumar et al
112
 5/52 (9.6%) 25/137 (18.2%) n.s 
HCC: hepatocellular carcinoma, n.s: not statistically significant 
 
3. Toxic substances: 
 Non-cirrhotic HCC can also occur due to the exposure of 
following genotoxic agents: 
i. Aﬂatoxin B1, a toxin produced by the fungus Aspergillus 
ﬂavus can contaminate many food products, such as cereals, 
nuts, spices, ﬁgs and dried fruit. This contamination is 
common in developing countries like India and other parts of 
Asia and Africa with a high HCC incidence.
44
A study by Qian 
et al
45
 has linked the association the urinary excretion of 
aﬂatoxin metabolites with a 4-fold increase in HCC risk. 
Infact, HBV infection increases the HCC risk in 
aflatoxinexposure to 60-fold when compared to the general 
population. Ming et al
46
 has shown that HBV infection 
sensitizes hepatocytes to the aﬂatoxin-induced 249ser-p53 
mutation. 
ii. Industrial carcinogens (such as azo-dyes, organic solvents, 
vinyl chloride, pesticides, nitrosamines, arsenic, aromatic 
amines) and substances derived from tobacco (benzopyrene) 
have been shown to havehepato-carcinogenic potential in 
animal studies. Hence, these substances could also play a role 
in human carcinogenesis. 
iii. Thorotrast (Radioactive elements) may also cause HCC, albeit 
much less frequently than angiosarcoma and 
cholangiocarcinoma.
47
 
iv. Finally, tissue iron overload may act as a co-carcinogen factor, 
as suggested by the frequent observation of mild parenchymal 
iron excess in the non-tumorous liver tissue of most patients 
with non-cirrhotic HCC.
48,49,50
 
 
4. Inherited diseases: 
 The development of non-cirrhotic HCC may also be attributed to 
rare inherited disorders such as: 
i. Metabolic diseases such as hereditary hemochromatosis, 
alpha-1-antitrypsin (AT) deficiency, porphyria, hyper-
citrullinemia and type I glycogen storage diseases.
24,51
 
ii. Congenital diseases like congenital hepatic fibrosis and 
Alagille’s syndrome. 
iii. Hepatic vascular abnormalities, which are associated with 
inherited coagulation disorders such as Budd-Chiari 
syndrome, hepato-portal sclerosis and nodular regenerative 
hyperplasia.
24
 
5. Steroid hormones: 
 Many case reports have described the development of HCC in 
non-cirrhotic patients with anabolic steroids taken for therapeutic 
purpose.
52,53
 Although many studies have reported an higher risk for 
HCC in patients taking oestrogen for 8 years or more, a direct 
etiological role of contraceptive steroids is not yet established.
54,55
 
Forman et al
54
 have demonstrated that oestrogen acts as initators or 
promotors of carcinogenesis and also produce cellular and vascular 
changes thus amplifying an already developing tumor. 
6. Genetic mutations:  
Zuckmann-Rossi et al
56
 postulated that the monoclonal mutations 
of both oncogenes and anti-oncogenes in hepatocellular adenoma are 
associated with the malignant transformation. Particularly, the gain of 
function mutation of β-catenin, which is found in 15-20% of 
hepatocellular adenomas are most likely to be associated with malignant 
transformation.
57
 
Familial clustering of HCC has also been reported and a recent 
study by Hassan et al
58
 has demonstrated that family history of liver 
cancer significantly increases the HCC risk irrespective of the HBV and 
HCV status. But, this study does not analyze separately for non-cirrhotic 
patients. However, it can be assumed that the possible relationship 
between a positive family history and HCC risk is the end result of 
environmental, genetic, behavioural and clinical risk factors.
58
 
 The molecular mechanisms of carcinogenesis involved in non-
cirrhotic liver are beginning to be explored. Recently, Chaubertet al
59
 
reported a germ line mutation in tumor suppressor gene, p10
INK4
 (MTSI) 
gene in 23% of European patients with non-cirrhotic liver and in 8% of 
cirrhotic HCC patients. Although these studies support the existence of 
familial form of carcinogenesis, the confirmation of hereditary 
component in HCC risk awaits further studies of familial clusters. 
HEPATO-CARCINOGENETIC PATHWAY: 
 Different authors have postulated different hepato-carcinogenetic 
pathway in non-cirrhotic HCC. This hypothesis is based on different 
scenario of genetic alteration found in non-cirrhotic HCC, that is, a 
tendency towards a low incidence of p53 mutation and a high rate of β-
catenin mutation, p14 inactivation and global gene methylation in non-
cirrhotic HCC.
60
 
Two recent studies by Chiappiniet al
61
 and Togni et al
62
 have 
found the presence of microsatellite instability (MSI), a sign of defect in 
DNA mismatch repair, in non-cirrhotic HCC patients with non-alcoholic 
and non-virally infected livers.  
PATHOLOGY: 
 The non-tumor bearing portion of liver in patients with non-
cirrhotic HCC usually show steatosis, steato-hepatitis, varying degree of 
fibrosis, iron excess or other metabolic disorder and hence only few 
cases show a normal parenchyma.
25,26,29
 In addition, large cell dysplasia 
is seen in 25-40% of cases.
25,63
 This figure reduces to 6-20% in patients 
with non-fibrotic liver.
29,49
 
 Most (50-85%) non-cirrhotic patients with HCC present as a 
large, solitary mass (about 10cm in most series).
26, 64-67
Multinodularity is 
not as common (18% vs. 34%) as seen in cirrhotic HCC
26
. This is 
possibly due to both the delay in presentation and distinct mechanism of 
hepato-carcinogenesis in non-cirrhotic HCC. 
 According to World Health Organization (WHO) histological 
classification, the trabecular type is the most common type (40-75%) in 
both non-cirrhotic HCC, and cirrhotic HCC.
25-27,49,56
 The scirrhous type 
and mixed hepatocellular/cholangiocellular carcinoma tend to occur 
more commonly in a non-cirrhotic background
68,69
, whereas 
Fibrolamellar HCC is almost exclusively limited to non-cirrhotic liver 
(115 vs. 1.5%).
27
 
 Two larger studies by Nzeakoet al
27
 and Shimada et al
29
 have 
shown that encapsulation is more common in non-cirrhotic HCC, 
however, this finding has not been confirmed in other studies.  
 A recent series by Trevisaniet al
26
 have demonstrated that the 
extra-capsular extension of HCC (invasion of surrounding structure 
and/or metastases) is more common in non-cirrhotic HCC when 
compared to cirrhotic HCC. 
 Although the more advanced stage of tumor at presentation in 
non-cirrhotic patients can be attributed to delayed diagnosis, a greater 
biological aggressiveness cannot be excluded, because some authors 
have reported poor tumor differentiation and early portal vein invasion 
in non-cirrhotic HCC.
11,29
 At present, the available data on this issue is 
controversial, as other authors have reported opposite results.
9,26,27
 
DIAGNOSIS: 
 According to the current international guidelines for the 
management of HCC, routine ultrasonographic surveillance is now 
being performed in all patients with chronic liver disease. This has 
resulted in early detection of tumor, usually before the manifestation of 
clinical symptoms. In contrast, in otherwise healthy person or with 
undiagnosed liver disease, HCC are generally detected late, usually after 
the appearance of symptoms such as abdominal pain or discomfort in 
right upper quadrant, jaundice or toxic syndrome (anorexia, weight loss, 
malaise, asthenia, fever).
35 
Trevisani et al
26
 have reported that non 
cirrhotic patients with HCC has a symptomatic presentation in about 
80% with the remaining being detected incidentally. This finding 
suggests that the delay in presentation and diagnosis accounts for most 
differences in pathological differences between non-cirrhotic and 
cirrhotic patients.  
 Most studies have demonstrated that the serum α-fetoprotein 
(AFP) level rarely exceeds 40ng/dl in non-cirrhotic when compared to 
cirrhotic patients with HCC (30-67% vs. 60-85%).
26,27,64,65
 This suggests 
the likely role of cirrhosis as independent promoter of moderate AFP 
elevation. However, the prevalence of level of AFP considered 
―diagnostic‖ for HCC is similar in both the groups.26,64 
PREOPERATIVE EVALUATION: 
 The preoperative investigations for HCC should focus on three 
main issues: 
1. Tumor status 
2. Underlying liver status 
3. Patient performance status. 
1. Tumor status: 
Assessment of tumor extent is best achieved with cross sectional 
imaging such as dynamic contrast enhanced Magnetic resonance 
imaging (MRI) and/or 4-phase multi-detector Computerized tomography 
(Figure: 10-12). There are no data at present to support the value of PET 
scanning in HCC.  A chest X-ray, CT chest and Bone scan are 
recommended to rule out extra-hepatic disease. Many studies have 
shown that the most common sites of metastatic spread of HCC are 
lung, bone, peritoneum and adrenals. Although these sites of spread may 
be detected by standard imaging techniques, peritoneal disease requires 
staging laparoscopy.  
2. Underlying liver status: 
 Blumgart et al
18
 have demonstrated that a healthy, non-cirrhotic 
liver may tolerate a resection of up to 80% due to the enormous 
regenerative capacity of liver. However, such favorable responses 
cannot be taken up for granted for extended hepatic resections. The risk 
of clinically significant liver insufficiency can be avoided only if there is 
50% reduction in functioning liver parenchyma even in non-cirrhotic 
liver. Although helpful, the Child-Pugh score and Model for end-stage 
liver (MELD) score are not adequate to select patients for major hepatic 
resection.  
 Most centers in Asia perform indocyanine green clearance  
(ICG-15) at 15 minutes as defining criterion for selection of liver 
resection.  Another important indicator of post-operative liver 
insufficiency is the pre-operative evaluation of the post-operative future 
liver remnant (FLR). CT is used to assess the ratio of future remnant 
(FLR) and total liver volume (TLV). The consensus panel recommends 
that this ratio should be at least 30-40% in non-cirrhotic patients.  
In patients with estimated FLR/TLV below the recommended values, 
pre-operative portal vein embolization (PVE) should be considered. 
ROLE OF PRE-OPERATIVE PORTAL VEIN EMBOLIZATION 
(PVE): 
 PVE produces atrophy in portion of liver to be resected and 
compensatory hypertrophy in the portion of liver to be preserved. By 
reducing the risk of liver failure, complication rate and hospital stay, 
PVE increases the safety of resection and expand the indication for liver 
resection in otherwise poor candidates for hepatectomy.
18
 
  A recent meta-analysis by Abulkhiret al
70
 have reviewed 37 
published series of preoperative PVE in 1088 patients (265 patients with 
HCC, the reminder with cholangiocarcinoma or liver metastases). In 2-4 
weeks, there was significant hypertrophy of FLR that was independent 
of technique and 85% of patients underwent planned liver resection. The 
reasons for not operating in remaining 15% of patients were inadequate 
hypertrophy (n=18), tumor progression (n=43), extra-hepatic spread 
(n=35) and other reasons such as refusal for surgery, poor medical 
condition, altered treatment approach for variety of reasons (n=35). In 
patients who underwent laparotomy, 27 patients were found 
unresectable, mainly due to advanced or unresectable disease. Of the 
remaining patients who underwent liver resection, transient liver failure 
was seen in only 2.5% (n=23), and death due to acute liver insufficiency 
in 0.8% (n=7). 
ROLE OF PRE-OPERATIVE TACE: 
 The role of TACE in pre-operative setting remains conflicting. In 
a RCT by Wu et al, there was no significant difference in overall 
survival or disease free survival. In addition, they have reported higher 
incidence of extra-hepatic recurrence with pre-operative TACE possibly 
due to easier tumor cell dislodgement during surgery.
71
 
 Similarly, Shimada et al
72
 have found pre-operative TACE to be a 
poor prognostic factor in univariate analysis, but not in multivariate 
analysis. The potential disadvantages of pre-operative TACE are 
impairment of pre-operative liver function, delayed in planned surgery 
and difficult surgery due to development of collateral vessels and severe 
inflammatory changes around tumor. At present, there is no sufficient 
data to support pre-operative TACE in HCC. 
STAGING: 
 Numerous staging systems have been proposed for clinical 
classification of HCC. The standard classification in any cancer is based 
on TNM staging, however in HCC, the 7
th
 TNM classification has 
several limitations.
73
 First, microvascular invasion is assessed by 
pathology, hence only available in patients (~ 20%) undergoing surgery. 
Second, it does not include information regarding liver function status or 
patient performance status.  The more popular Child-Pugh classification 
and Okuda staging serve only to class prediction in HCC patients. The 
five more comprehensive staging that have been broadly tested are: 3 
European [ the Barcelona Clinic Liver cancer (BCLC)
74
 staging, the 
cancer of liver Italian program (CLIP) 
75
classification, the French 
classification
76
] and 2 Asian [the Chinese University Prognostic Index 
(CUPI)
77
 score and the Japan Integrated staging with biomarkers (bm-
JIS)
78
 ]. Overall, the most external validated staging systems are BCLC, 
CUPI, CLIP and bm-JIS with only two include prognostic variables 
(BCLC and CUPI) and only one  (BCLC) assign treatment allocation to 
specific prognostic subgroups. Hence the current EASL-EORTC 
guidelines recommend BCLC for staging HCC.
79 
 
TREATMENT AND SURVIVAL: 
The various treatment options for non-cirrhotic patients with HCC are: 
1. Hepatic resection 
2. Liver transplantation 
3. Trans-arterial embolization 
4. Radio-embolization 
5. Radio-frequency ablation 
6. Systemic chemotherapy 
 
1. HEPATIC RESECTION: 
Regardless of etiology, the optimal management in HCC is 
complete resection of tumor. Numerous studies have shown that the 
patients with non-cirrhotic HCC undergo resection more than the 
reported (12-28%) incidence in patients with underlying cirrhosis.
80,81
  
In spite of large tumor size, the preserved liver function in non-cirrhotic 
patients allows major hepatic resections to be performed quite safely.  
 In fact, despite major hepatic resection, the post-operative morbidity 
and mortality are rather low in these patients.
7,11,66,67,82
Moreover, the 
overall survival and recurrence free survival are better in non-cirrhotic 
patients with HCC than in patients with cirrhosis.
9,11,29,83,84
 
The overall survival and disease-free survival of patients resected 
for non-cirrhotic HCC are depicted in Table16. The 5-year overall 
survival rate ranges between 25% and 81% with best figures reported in 
in non-cirrhotic HCC. Similarly, the 5-year disease-free survival ranged 
from 24% to 58% with best value achieved in non-cirrhotic patients.
82
 
The independent factor for overall survival in patients with non-
cirrhotic HCC is the rate of tumor recurrence, which varies between 
27% and 73% in different series, as outlined in table-16.
82
 Most (2 out 
of 3) recurrences occur in the initial two post-operative years, but can be 
delayed to 10 years or more. Up to 40% recurrences are amenable to 
second hepatectomy, but long-term survivals are noted in patients with 
early recurrence. These results highlight the importance of follow-up 
during the first two post-operative years and the need for prolonged 
surveillance for aggressive management of recurrences.
7,10,65,67,82,83,85
 
2. LIVER TRANSPLANTATION: 
 The role of orthotopic liver transplantation (OLT) in treatment of 
patients with non-cirrhotic HCC is a subject of controversy.  
A systematic review conducted by Houbenet al
6
 included all published 
series of OLT for non-cirrhotic HCC performed between 1966 and 1998 
has shown that the long-term survival in these patients is poor with 5-
year survival rate of 11%. This dismal figure suggest the advanced 
tumor stage at the time of OLT, which resulted in recurrences in about 
50% of patients, mostly (>75%) in the first 2 years, indicating the likely 
possibility of extra-hepatic micrometastases.
6
 
 The specific selection criteria for transplantation in non-cirrhotic 
HCC are lacking. The commonly adopted criteria in non-cirrhotic HCC 
patients are actually proposed for cirrhotic patients, which is 
inappropriate because most non-cirrhotic HCC are outside the Milan 
criteria at the time of diagnosis and those fulfilling these criteria are 
potentially resectable tumors. In addition, the tendency towards OLT in 
non-cirrhotic HCC is limited by the report that the outcome after 
resection in non-cirrhotic HCC within Milan criteria is comparable to 
that expected in cirrhotic patients transplanted within Milan criteria. 
Pragmatically, OLT could be reserved as a salvage treatment for non-
cirrhotic patients with post-resection tumor recurrence and those with 
high risk of post-hepatectomy liver failure.
9,85
 
3. TRANS-ARTERIAL EMBOLIZATION: 
 The basic physiological principle that makes TAE feasible is that 
most of blood supply (90% to 100%) to liver tumors is derived from the 
hepatic artery, thus embolization of tumor-feeding arteries leads to 
selective ischemic damage of the tumor, while sparing the normal liver 
parenchyma supplied mainly by the portal vein. Moreover the 
pharmacokinetic advantage of selective loco-regional drug 
administration further enhances the theoretic benefit. 
Basically there are three types of trans-arterial therapy: 
1. Trans-arterial embolization (TAE) with bland particles. 
2. Trans-arterial chemo-embolization (TACE) with or without 
lipiodol. 
3. Trans-arterial chemotherapy (TAC) alone or with lipiolol. 
A meta-analysis by Camma et al
86
 have failed to demonstrate any 
significant survival differences between TAE and TACE, in spite of 
a trend towards longer survival with TACE.  
Indications for TACE: 
1. Unresectable large hypervascular liver tumor. 
2. Intermediate BCLC stage HCC (Okuda staging 1 to 2, 
Performance score 0 and large or multinodular HCC) 
3. Spontaneous rupture of HCC 
4. As neoadjuvant therapy to downsize tumor before resection or 
bridging therapy in patients awaiting liver transplantation. 
Contraindication to TACE: 
1. Extensive tumor involvement of more than 50% to 70% of liver 
and class C cirrhosis. 
2. Main portal vein occlusion. 
3. Active gastrointestinal bleeding, extra-hepatic spread, hepatic 
encephalopathy and biliary obstruction. 
4. Anaphylactoid reaction to contrast agents, cardiac or renal 
insufficiency, uncorrectable coagulopathy and severe peripheral 
vascular disease.  
The mean diameter of tumor treated by TACE was 5.2cm in 
randomized controlled study by Llovet et al
87
 and 5cm in GETCH
88
 
(Grouped Etude et de Traitement du CarcinomeHepatocellulare ) study. 
In addition to tumor size, factors such as good liver function, 
performance status – 2, Okuda stage II were associated with survival 
benefit. However, tumor size >5cm is a strong negative factor affecting 
survival after TACE. 
 The survival benefit from TACE was not demonstrated in 3 early 
randomized controlled trails (RCT) by Pelletier et al
89
 (1990), Grouped 
Etude et de Traitement du Carcinome Hepatocellulare
88
 (GETCH study-
1995) and Camma et al
86
 (2002). However, 2 newer RCT’s from 
Barcelona (Llovetet al
87
, 2002) and Hongkong (Lo et al
90
, 2002) 
demonstrated significant survival advantage with TACE. A recent meta-
analysis of all RCTs published from 1978 to 2002, American 
Association for study of liver diseases (AASLD-2005, Bruix and 
Sherman et al
35
) and European association for study of liver (EASL-
2001, Bruix et al
5
) have recommended TACE as first line non-curative 
therapy for non-surgical patients with large or multifocal HCC without 
vascular invasion or extra-hepatic spread.  
 A recent advancement in TACE is the usage of drug eluting beads 
(DEBs) which slowly releases chemotherapeutic drug thereby reducing 
the systemic toxicity. Early results are promising but most series are 
associated with short-term follow-up only.
91
 
4. RADIO EMBOLIZATION or SELECTIVE INTERNAL 
RADIATION THERAPY (SIRT): 
 Radio-embolization is a method of delivering localized radiation 
dose of up to 150 Gy to tumor thereby reducing the complication of 
external radiation. 
90
Yttrium is the most commonly used radioactive 
element for radio-embolization. It is a pure β-emitter with tissue 
penetration ranging from 2.5 to 11mm. Radio-embolization was 
first studied by Nolan and Grady
92
 (1969) using 
90
Yttrium oxide 
(
90
Y2O3) contained in metal particle of 50-100 µm in size. Their study 
was limited by small number of patients but showed a favorable 
response with decrease in tumor size. The subsequent 
90
Y study was 
published by Mantravadiet al
93
 (1982) concluding that patients with 
hypervascular tumor are more likely to be benefit from radio-
embolization.  Based on animal safety studies, Shepherd et al
94
 
conducted phase I studies suing 
90
Y glass microspheres and reported that 
doses of up to 150 Gy were tolerable with minimal toxicities. In view of 
the encouraging results, a phase II study performed by same authors 
showed a 20% response rate with doubling of survival duration (635 vs. 
323 days) in patients who underwent radio-embolization.  
 Analysis from these studies and other trials have demonstrated 
that tumor-liver ratio <2, low Okuda stage, low AFP favored longer 
survival whereas elevated bilirubin was associated with post-treatment 
liver dysfunction.
95
 The role of radio-embolization in HCC patients is 
evolving and further trials are needed to document their safety and 
clinical efficacy.  
5. RADIOFREQUENCY ABLATION: 
 Radiofrequency ablation (RFA) destroy tumor by generating heat 
within a lesion. During RFA, a high frequency alternating current 
changes the direction of ions around an alternating electrode. This 
produces frictional heating of tissues and when tissue temperature 
increases above 60
0 
C, loss of cellular structure and protein denaturation 
occurs, resulting in cell death. RFA can be performed by percutaneous, 
laparoscopic or open (laparotomy) approach.  
 Clinical trials of RFA for HCC have shown promising results 
andLivraghiet al
96
 showed a local response rate of only 2.8% at a 
median follow-up of 31 months. Poon et al
97
 demonstrated a complete 
response rate of 91% for large (>3cm) HCC and showed rate of local 
recurrence, distant recurrence were independent of tumor size. Two 
randomized control trials by Chen et al
98
 and Lu et al
99
 have 
demonstrated therapeutic equivalence of RFA, when compared with 
resection in small HCC, until more prospective studies have been 
performed, resection remains the initial choice in these patients.  
6. SYSTEMIC CHEMOTHERAPY: 
 The role of systemic chemotherapy is very limited in patients with 
HCC. The response rate with single agents is about 10% to 15%.
100
  
A recent retrospective study by Edelineet al
101
 reported that combination 
chemotherapy with Epirubicin, cisplatin, and 5-flurouracil/ capecitabine 
was associated with objective response in 25% of cases with 
unresectable HCC.  
 Lau et al
102
 have shown that 10% of advanced HCC patients 
underwent successful resection after tumor downsizing with 
combination chemotherapy composed of Cisplatin, interferon alfa, 
Adriamycin and 5-flurouracil (PIAF) regimen. The 3-year survival rate 
was 53% for those who underwent resection following PIAF regimen. In 
the multivariate analysis of 149 patients who received PIAF by the same 
author, non-cirrhotic patients with normal bilirubin level had a shown a 
better response to combination chemotherapy. 
 New molecular drug, Sorafenib which is an oral multi-kinase 
inhibitor that targets Raf kinase and receptor tyrosine kinase has shown 
promising results in phase III randomized placebo controlled (SHARP 
trial) trial
103
 involving 602 patients with advanced HCC in terms of 
improved survival and median time to progression. This result has 
suggested sorafenib as first line therapy for patients with advanced 
HCC, although no patient is reported to have tumor downsized to 
undergo resection. Hence, the optimal management of patients with 
advanced and unresectable HCC is not yet established. 
MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
STUDY DESIGN: 
Prospective study 
STUDY PERIOD: 
September 2010 to December 2012 
INCLUSION CRITERIA: 
All consecutive patients with histologically proven HCC in non-
cirrhotic, non-fibrotic liver undergoing liver resection will be included 
in the study 
EXCLUSION CRITERIA: 
1. Patients undergoing liver resection with palliative intent were 
excluded from the study. 
2. Histological proven HCC in cirrhotic or fibrotic background. 
3. Patient refuses to give informed consent to be included in the 
study. 
 METHODOLOGY: 
PATIENTS: 
 Between August 2010 and December 2012, 76 patients with HCC 
underwent liver resection in the Institute of Surgical gastroenterology 
and liver transplantation at Government Stanley Medical College and 
Hospital. Of the 76 patients who had liver resections for HCC, 30 
patients had no underlying parenchymal liver disease (no cirrhosis or 
fibrosis) and these 30 patients were included in the study  
PREOPERATIVE EVALUATION: 
  Routine pre-operative evaluation include recording of detailed 
demographic profile, history of presenting symptoms, physical 
examination and routine laboratory investigations like complete 
hemogram, renal function test with electrolytes, liver function test 
including albumin. Data regarding underlying liver disease (such as past 
or current hepatitis B virus or hepatitis C virus infection, alcoholic or 
non-alcoholic steatohepatitis, iron overload and hemochromatosis) and 
risk factors for the development of HCC such as chronic alcohol intake ( 
≥ 40 g/day), tobacco consumption (≥ 20 pack years), diabetes mellitus, 
overweight or obesity(BMI > 25 kg/m
2
), aflatoxin or carcinogenic 
substance exposure) were also recorded. Serum alpha fetoprotein and 
upper gastro-intestinal endoscopy were done in all patients.  
Pre-operative investigations performed to assess the extent of 
disease included Chest X-ray, abdominal ultrasonography, contrast 
enhanced computerized tomography (CT) and/or MRI in all patients and 
CECT thorax in selected patients. The diagnosis of HCC was based on 
either pre-operative imaging and serum AFP level or rarely biopsy. 
Liver function status was assessed by the Child-Pugh grading. Patient 
performance status at the time of diagnosis was determined according to 
the Eastern Co-operative Oncology Group (ECOG). 
SURGERY: 
 Prior to surgery, all patients were discussed in a multidisciplinary 
meeting in order to ensure an optimal management strategy. Staging 
laparoscopy was done immediately before surgery in all patients. In 
addition to evaluation of peritoneal deposits, staging laparoscopy 
allowed assessment of future liver remnant size and severity of cirrhosis, 
when major liver resection was planned. 
 The operation was performed through a Maakuchi’s incision or 
bilateral subcostal incision with an upward midline extension 
(Mercedez-Benz incision).  Intra-operative ultrasound was done in all 
cases to detect any additional tumor and relationship of tumor to 
vasculo-biliary structures.   Selective vascular inflow and outflow 
control was obtained followed by parenchymal transection under low 
central venous pressure (CVP) anaesthesia, using a combination of 
kellyclasia, harmonic, ultrasonic dissector and water jet.  
 Anatomic resections were defined according to the Brisbane 
terminology described by International Hepato-Pancreatico-Biliary 
Association (IHPBA) and Non-anatomical resections were defined as 
atypical or wedge resection with tumor free margin of at least 1cm. A 
major hepatic resection was defined as resection of 3 or more segments 
of liver according to Couinaud’s classification of liver segments and 
minor hepatic resection was defined as resection of 2 or less segments of 
liver. 
Intra-operative parameters like type of liver resection 
(Major/minor, anatomic/non-anatomic), duration of surgery, blood loss, 
number of blood transfusion and intra-operative complications were 
recorded. All patients received prophylactic broad-spectrum antibiotics. 
POST-OPERATIVE CARE: 
  All patients were monitored in the intensive care unit during the 
initial post-operative period. Careful attention was paid to hydration, 
oxygenation and tissue perfusion. Intravenous albumin and diuretics 
were administered in selected patients to reduce ascites. Early 
ambulation was encouraged and oral intake was resumed once the bowel 
activity was restored. Liver function test with prothrombin time and INR 
were routinely done in 1
st
, 3
rd
 and 5
th
 post-operative days to detect post-
operative liver insufficiency. All post-operative complications were 
recorded and were classified as: Infectious (Anastomotic leak, Intra-
abdominal abscess, Wound infection, Pneumonia, Septicemia) and Non-
infectious (Pulmonary embolism, Renal failure, Cardiac events 
including Acute coronary syndrome and Acute MI). Length of hospital 
as well as post-operative stay were recorded. 
HISTOPATHOLOGY:  
All the resected specimens were analyzed by the experienced 
pathologists. A standard histo-pathological assessment of tumoral and 
non-tumoral tissue was performed. 
 The macroscopic features of tumor such as size, number, tumor 
capsule and vascular invasion were recorded. Tumors were classified 
using World Health Organization criteria (such as trabecular, 
pseudoglandular, compact, scirrhous or mixed) and graded using 
Edmondson and Steiner classification into well-differentiated (grade I), 
moderately-differentiated (grade II) and poorly differentiated (grade III). 
A clear resection (R0) margin was defined as negative of 1mm from the 
inked margin or 1mm of liver tissue between capsule and margin. 
Macroscopic vascular invasion was defined as presence of tumor 
thrombi in right or left main branches of the hepatic veins or the portal 
veins. Microscopic vascular invasion was defined as presence of tumor 
emboli within central vein, capsular vessels or portal vein and hepatic 
vein radicles. 
Non-tumoral tissue was assessed in area distant to tumor to avoid 
inflammatory or fibrotic changes caused by tumor itself. Fibrosis and 
chronic activity were graded using the METAVIR grading system. 
Steatosis was graded according to the percentage of steatotic 
hepatocytes into mild (5% to 20%), moderate (20% to 50%) and severe 
(>50%). Iron overload was graded according to Modified Searle scale 
into mild or grade I (iron barely visible at low magnification but 
confirmed at high magnification, moderate or grade II (iron visible at 
low magnification and only in zone 1, and severe or grade III (iron 
visible at low magnification occupying most of acinus). Precancerous 
lesions in the non-tumoral liver were defines by the presence of liver 
cell dysplasia, clear cell foci or iron-free foci in otherwise iron-
overloaded liver. 
FOLLOW UP: 
All patients were followed up in the out-patient department, every 
month during the first 3 months, then every 3 months for initial 2 years 
and every 6months thereafter. In each visit, physical examination, liver 
function test, serum AFP and abdominal ultrasound was performed. 
 CT scan was performed at month 6 and then every year.  
The diagnosis of recurrence was based on clinical, laboratory 
(elevated serum AFP level) and radiological (abdominal ultrasound/CT, 
chest X-ray) findings. The number and pattern of recurrence 
(intrahepatic, extra-hepatic or both) were also recorded. Patients with 
isolated and resectable intra-hepatic recurrence underwent re-resection. 
All others were treated with TACE, systemic therapy or best supportive 
care.  
The follow up period of this study was closed in February 2013 to 
ensure that every patient had at least 2 months of observation following 
surgery. The above described protocol was approved by our institutional 
ethical committee. 
 STATISTICAL ANALYSIS: 
 All clinico-pathological and follow-up data were prospectively 
collected and entered with regular update of any tumor recurrence for 
each patient after each follow-up. Categorical variables were expressed 
as percentages and compared using chi-square test or Fisher exact test. 
Continuous variables were expressed as mean ± SD and compared using 
the student-t test. Survival and recurrence were expressed as median ± 
SEM. Patient survival and recurrence were calculated using the Kaplan-
Meier test and compared using the log-rank test. Clinico-pathological 
variables found to bear prognostic significance in univariate analysis 
were entered into Cox multivariate proportional hazard model to 
determine which of these factors possessed independent predictive 
value. p-value< 0.05 was considered statistically significant and analysis 
was carried out using the Statistical Package for the Social Sciences 
(SPSS 18.0; SPSS, Inc., Chicago, IL, USA) 
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RESULTS 
This prospective study was conducted in the Institute of Surgical 
gastroenterology and liver transplantation, Government Stanley Medical 
College and Hospital from August 2010 to December 2012. During the 
study period, a total of 76 patients underwent liver resection for 
hepatocellular carcinoma.  Of the 76 patients who had liver resections 
for HCC, 30 patients (39.47%) had no underlying parenchymal disease 
(no cirrhosis or fibrosis) and were included in the study. 
  The clinical characteristics of 30 patients with non-cirrhotic 
HCC are shown in table-4. The mean age at presentation was 48.23 
years (range: 13-77). The age distribution (Figure 2) of 30 patients 
shows that the majority of patients (67%) are in the fifth and sixth 
decades. The gender distribution (Figure 3) shows that there were 19 
males (63%) and 11 females (37%) with male: female ratio of 1.7: 1. 
Table 4: Clinical characteristics of 30 patients with HCC in non-
cirrhotic liver studied.  
Variables n % 
Age 
 <50 years 
 >50 years 
 
13 
17 
 
43 
57 
Sex 
        Male 
        Female 
 
19 
11 
 
63 
37 
 Risk factor 
Hepatitis B virus infection 
Hepatitis C virus infection 
Chronic alcohol intake 
Tobacco smoking 
Diabetes mellitus 
Obesity 
Unknown 
 
4 
0 
9 
9 
8 
3 
12 
 
13 
0 
30 
30 
26.7 
10 
40 
Symptoms 
Abdominal pain 
Weight loss and anorexia 
Abdominal mass 
Fever 
Jaundice 
Hepatomegaly 
 
30 
28 
7 
4 
2 
17 
 
100 
93 
23 
13 
6 
57 
ECOG performance status 
0 
1 
2 
 
26 
3 
1 
 
87 
10 
3 
Pre-operative biopsy 
Present 
Absent 
 
3 
27 
 
10 
90 
ECOG: Eastern Co-operative Oncology Group. 
 
The potential risk factors for the development of HCC were 
present in 18 patients (60%). Four patients (13%) presented with current 
or past hepatitis B viral infection and no patient was positive for anti-
HCV antibody. Tobacco and alcohol consumption were found in 9 
patients (30%). Diabetes mellitus was observed in 8 patients (26.7%) 
and overweight in 3 patients (10%). In contrast, 12 patients (40%) did 
not reveal any underlying risk factor for the development of HCC.   
Abdominal pain was the most common presentation in the non-
cirrhotic HCC patients, which was noted in all 30 patients (100%), 
followed by anorexia and weight loss in 28 patients (93%), abdominal 
mass in 7 patients (23%), fever in 4 patients (13%) and jaundice in 2 
patients (6%). None of the patient was asymptomatic at the time of 
presentation. Hepatomegaly was observed in 17 patients (57%) and none 
of the patients had ascites. Three patients had undergone pre-operative 
biopsy and none of the patient received any type of pre-operative 
treatment.  
The pre-operative laboratory investigations done in 30 patients 
with non-cirrhotic HCC were listed in table-5. The mean hemoglobin 
level was 10.7 g/dl ± 1.6 (range: 8.5-14). Serum bilirubin was elevated 
in 2 patients (6%). The mean serum bilirubin value was 1.1 mg/dl ± 0.83 
(range: 0.25-3.6). Serum aspartate transaminase (AST) was elevated in 
19 patients (63%) with mean value of 84.6 U/L ±91.45 (range: 21-498). 
Serum albumin was low in 17 patients (57%) with mean value of 3.42 
g/d ± 0.55 (range: 2.5-4.9). Serum alpha-fetoprotein level was normal in 
20 patients (67%) and elevated above 1000ng/ml in only 2 patients 
(6%). The mean AFP level was 6.8 ng/ml ± 5922.9 (range: 0.3-32476).  
Table 5: Pre-operative laboratory data in 30 patients with HCC in non-
cirrhotic liver studied.  
Laboratory parameter 
(unit) 
Normal 
range 
Mean ± Standard deviation 
(range) 
Hemoglobin (gm/dl) 14-18 10.73 ± 1.6 (8.5-14) 
Total leucocyte count 
(cells/cu.mm) 
4000-
11000 
8346.3 ± 2428 (2200-15000) 
NLR 1-8 x 10
9
/L 2.77 ± 1.58 (1.09-7.33) 
ESR (mm/hr) 0-20 41.6 ± 26.49 (8-120) 
Platelet (cells/cu.mm) 1.5 -4 3.71 ± 1.80 (1.42-7) 
Prothrombin Index 70-100% 97.36 ± 5.66 (77.77-100) 
INR 0.8-1.2 1.04 ± 0.09 (1-1.4) 
Sugar (mg/dl) <160 120.93 ± 48.85 (67-268)  
Urea (mg/dl) 10-50 21.67 ± 7.70 (13-50) 
Creatinine (mg/dl) 0.6-1.1 0.80 ± 0.24 (0.4-1.54) 
Bilirubin (mg/dl) 0-1 1.12 ± 0.83 (0.25-3.6) 
AST (U/L) 0-40 84.6 ± 91.45 (21-498) 
ALT (U/L)  0-37 47.66 ± 35.70 (8-173) 
GGT (U/L) 0-45 98.93 ± 196.27 (10-1050) 
SAP U/L) 0-290 261.87 ± 123.56 (85-617) 
Albumin (g/dl) 3.8-4.4 3.42 ± 0.55 (2.5-4.9) 
AFP (ng/ml) <20 6.8 ± 5922.9 (0.3-32476) 
NLR: Neutrophil-leucocyte ratio, ESR: Erythrocte Sedimentation rate, 
INR: Internationalized normalized ratio, AST: Aspartate transaminase, 
ALT: Alanine transaminase, GGT: Gamma-glutaryltransferase, SAP: 
serum alkaline phosphatase, AFP: Alpha feto-protein. 
 
The extent and type of resection performed were outlined in table-
6. Out of 30 patients, 25 patients (83%) underwent major hepatectomy 
whereas only 5 patients (17%) underwent minor hepatectomy (Figure 4). 
The most common procedure performed was right hepatectomy (Figure: 
13-16), which was done in 12 patients (40%), followed by left 
hepatectomy in 6 patients (20%), extended right hepatectomy in 5 
patients (17%), bi-segmentectomy in 2 patients (6.7%) and extended left 
hepatectomy, central hepatectomy, left lateral segmentectomy (Figure 
17 and 18) in 1 patient (3.3%) each. Non-anatomical resection was done 
in 2 patients (6.7%). Three patients (10%) underwent enbloc resection of 
adjacent organ (diaphragm) involvement to achieve R0 resection.  
Table 6: Type and extent of liver resection in 30 patients with HCC in 
non-cirrhotic liver studied.  
Surgical procedures  n % 
Major Hepatectomy (n=25) 
Right Hepatectomy 
Left Hepatectomy 
Extended Right Hepatectomy 
Extended Left Hepatectomy 
Central hepatectomy 
 
12 
6 
5 
1 
1 
 
40 
20 
16.7 
3.3 
3.3 
Minor Hepatectomy: (n=5) 
Left lateral segmentectomy 
Bisegmentectomy 
Non-anatomical resection 
 
1 
2 
2 
 
3.3 
6.7 
6.7 
 
The mean duration of operation was 2.45 ± 0.59 hours (Table-7). 
The mean blood loss during surgery was 216.5 ± 119.32 ml (range: 100-
720ml). There was a need for blood transfusion in 2 patients (6.7%).  
Table 7: Perioperative factors in 30 patients with HCC in non-cirrhotic 
liver studied.  
Peri-operative factors 
Mean ± Standard deviation or 
n (%) 
Operative time (hours) 2.45 ± 0.59 
Blood loss (ml) 216.5 ± 119.32 
Need for blood transfusion 2 (6.7%) 
Mean post-operative stay (days) 16.7 ± 7.0 
Morbidity 15 (50%) 
Mortality 1 (3.4%) 
The mean post-operative length of stay was 16.7 ± 7.0 days. 
(range: 9-35 days). In-hospital mortality was noted in 1 patient (3.4%) 
due to post-operative liver failure.  
The data regarding the post-operative complication was 
summarized in table-8. Overall, the post-operative complications 
occurred in 15 patients (50%). The most common post-operative 
complication (Figure 5) was intra-abdominal collection and wound 
infection noted in 6 patients (20%) each, followed by sepsis in 5 patients 
(16.7%), Post-operative liver failure and chest infection in 4 patients 
(13.4%) each. Bile leak was noted in 3 patients (10%) and renal failure 
in 1 patient (3.4%).  
Table 8: Overall postoperative complications occurred in 15 of 30 
patients with HCC in non-cirrhotic liver studied.  
Post-operative 
complications 
n % 
Death 
(3.4%) 
Intra-abdominal collection 6 20  
Post-operative liver failure 4 13.4 1 
Renal failure 1 3.4  
Chest infection 4 13.4  
Wound infection  6 20  
Bile leak 3 10  
Sepsis 5 16.7  
 
The mean size of tumor on histo-pathological examination was 
13.2 ± 5.22 cm (range: 5-25cm). The majority of patients (76.7%) had 
solitary tumor (Table-9). Tumor encapsulation was noted in 19 patients 
(63.3%) with capsular invasion of tumor observed in 5 patients (26.3%). 
Histological differentiation of tumor was grade I in 13 patients (43.3%), 
grade II in 8 patients (26.7%) and grade III in 9 patients (30%). 
Microvascular invasion was observed in 15 patients (50%) but none of 
the patient had macrovascular invasion. The resected margin was found 
positive for tumor cells in 8 patients (26.7). The surrounding non-tumor 
liver showed steatotic changes in 4 patients (13.3%).  
Table 9: Histo-pathologic characteristics of tumor and surrounding 
parenchyma in 30 patients with HCC in non-cirrhotic liver studied.  
Variables n % 
Size 
 <6cm 
 >6cm 
 
5 
25 
 
16.7 
83.3 
Number of tumor 
           Solitary 
           Multiple 
 
23 
7 
 
76.7 
23.3 
Encapsulation 
           Present  
          Absent 
 
19 
11 
 
63.3 
36.7 
Differentiation 
           I 
           II 
           III 
 
13 
8 
9 
 
43.3 
26.7 
30.0 
Microvascular invasion 
          Present 
          Absent 
 
15 
15 
 
50.0 
50.0 
Macrovascular invasion 
          Present 
          Absent 
 
0 
30 
 
0.0 
100 
Capsular invasion 
          Present 
          Absent 
 
5 
14 
 
26.3 
73.7 
Margin 
          Positive 
          Negative 
 
8 
22 
 
26.7 
73.3 
Steatosis 
          Present 
          Absent 
 
4 
26 
 
13.3 
86.7 
pTNM-(AJCC-7
th
 edition) 
         I 
         II 
         III 
         IV 
 
6 
14 
9 
1 
 
21 
45 
29 
5 
Okuda stage 
          I  
         II 
         III 
 
9 
20 
1 
 
30 
67 
3 
pTNM: pathologic tumor-node-metastasis 
 
The follow-up rate was 100% with median follow-up of 405 days 
(range: 62-921 days). In the whole study population, tumor recurrence 
was identified in 14 patients (46.6%) within the follow-up period(Table-
10). Of these 14 patients, 5 patients (35.7%) had isolated intra-hepatic 
recurrence, 3 patients (21.4%) had isolated extra-hepatic recurrence and 
6 patients (42.8) had both intra-hepatic and extra-hepatic recurrence. Of 
the 5 patients with isolated intra-hepatic recurrence, 2 patients 
underwent re-resection, 2 patients received systemic chemotherapy and 
1 patient was managed with supportive care. Two patients with isolated 
extra-hepatic recurrence and 2 patients with both intra and extra-hepatic 
recurrence were treated with systemic chemotherapy. The remaining 1 
patient with isolated extra-hepatic recurrence and 4 patients with 
multiple recurrences were managed symptomatically.  
Table 10: Pattern of recurrence and its management in 14 of 30 patients 
with HCC in non-cirrhotic liver studied.  
PATTERN OF RECURRENCE 
(n=14) 
n % 
Isolated Intra-hepatic recurrence 
Unifocal 
Multifocal 
 
3 
2 
 
21.4 
14.2 
Isolated Extra-hepatic recurrence 
Lung 
Bone 
 
2 
1 
 
14.2 
7.1 
Both Intra-hepatic and Extra-hepatic 
Unifocal intra-hepatic + 
Extrahepatic 
Multifocal intra-hepatic + 
Extrahepatic 
 
2 
4 
 
14.2 
28.6 
 
MANAGEMENT OF RECURRENCE   
Intra-hepatic alone 
Re-resection 
Systemic chemotherapy 
Best supportive care 
 
2 
2 
1 
 
Extra-hepatic alone 
Systemic chemotherapy 
Best supportive care 
 
2 
1 
 
Both Intra-hepatic and Extra-hepatic 
Systemic chemotherapy 
Best supportive care 
 
2 
4 
 
 
OVERALL SURVIVAL: 
At the time of analysis, there had been 11 deaths (36.7%) with 19 
survivors (63.3%). The overall 1-, 2-, 3- year survival rates for the entire 
study group are 86.7%, 66.7% and 63.3% respectively.  At the end of 1, 
2, 3 year, there were 26, 20, 19 alive patients respectively.   
PROGNOSTIC FACTORS FOR OVERALL SURVIVAL:  
 Patient who died after operation were excluded from the analysis 
of prognostic factors for overall survival after liver resection for HCC in 
non-cirrhotic patients. In the univariate analysis, high grade tumor  
(p = 0.007), prothrombin time(p = 0.046) and serum bilirubin level  
(p = 0.034) were significant predictors of poor long term survival 
(Table-11). In the multivariate analysis, only high grade tumor (p = 
0.039) was identified as independent prognostic factor (Figure 6) for 
overall survival after liver resection for HCC in non-cirrhotic patients 
(Table-12). 
Table 11: Clinico-pathological and operative prognostic factors for 
overall and disease-free survival in 30 non-cirrhotic HC patients 
(Univariate Analysis) 
 
Characteristics 
OVERALL SURVIVAL DISEASE-FREE 
SURVIVAL 
n % p-value n % p-value 
Age (yrs) 
<60 
>60 
 
11 
19 
 
18 ± 2.6 
29 ± 2.23 
0.458  
14 
16 
 
22 ± 1.9 
33 ± 2.21 
0.625 
Gender 
Male 
Female 
 
12 
18 
 
11 ± 2.5 
28 ± 2.75 
0.223  
11 
19 
 
19 ± 2.7 
26 ± 3.9 
0.097 
HBs antigen 
Positive 
Negative  
 
4  
26 
 
25 ± 4.6 
33 ± 1.9 
0.792  
3  
27 
 
13 ± 7.1 
27 ± 3.8 
0.511 
Alcohol intake 
Yes 
No 
 
4 
26 
 
31 ± 3.9 
39 ± 4.1 
0.091  
7  
23 
 
16 ± 4.6 
21 ± 2.9 
0.351 
AFP (ng/ml) 
<20 
>20 
 
9 
21 
 
39 ± 2.3 
27 ± 1.9 
0.191  
17 
13 
 
26 ± 4.59 
30 ± 2.77 
0.055 
Bilirubin (mg/dl) 
<1.5 
>1.5 
 
3 
27 
 
23 ± 7.3 
11 ± 1.8 
0.034*  
3  
27 
 
18 ± 6.53 
29 ± 2.32 
0.012* 
Prothrombin 
time  
<15 sec 
>15 sec 
 
26 
4 
 
25 ± 1.7 
13 ± 1.9 
0.046*  
28 
2 
 
27 ± 2.32 
11 ± 0.51 
0.041* 
Albumin (g/dl) 
<3 
>3 
 
5 
25 
 
16 ± 4.9 
46 ± 2.7 
0.061  
3 
27 
 
12 ± 0.82 
29 ± 2.31 
0.241 
Size (cm) 
<6 
>6 
 
11 
19 
 
17 ± 2.8 
26 ± 1.7 
0.576  
14 
16 
 
18 ± 7.51 
31 ± 1.92 
0.061 
Number 
Solitary 
Multiple 
 
26 
4 
 
15 ± 6.5 
21 ± 2.4 
 
0.061  
25 
5 
 
18 ± 6.6 
29 ± 2.33 
0.180 
Capsule 
Present  
Absent  
 
11 
19 
 
25 ± 1.7 
33 ± 1.9 
0.106  
14 
16 
 
23 ± 6.1 
27 ± 3.21 
0.210 
Grade  
High  
Low  
 
21 
9 
 
32 ± 1.8 
25 ± 4.4  
0.007*  
21 
9 
 
30 ± 1.99 
12 ± 0.71  
0.001* 
Vascular 
invasion 
Present  
Absent 
 
12 
18 
 
13 ± 1.7 
21 ± 6.4 
0.07  
15 
15 
 
20 ± 5.45 
32 ± 1.79 
0.0001* 
Capsular 
invasion 
Present  
Absent   
 
12 
18 
 
13 ± 1.7 
21 ± 6.4 
0.07  
3 
27 
 
11 ± 0.61 
30 ± 7.1 
0.266 
Steatosis 
 Present  
Absent  
 
4 
26 
 
15 ± 1.9 
18 ± 2.6 
0.576  
3  
27 
 
20 ± 2.19 
29 ± 2.2 
0.082 
Major resection 
Yes  
No  
 
17 
13 
 
29 ± 1.92 
21 ± 0.60 
0.069  
20 
10 
 
31 ± 6.7 
22 ± 7.1  
0.351 
Blood 
transfusion 
Yes 
No  
 
2 
28 
 
18 ± 0.09  
31 ± 2.4 
0.199  
2 
28 
 
11 ± 0.50 
27 ± 2.31  
0.012*` 
Post-op stay 
(days) 
<15 
>15 
 
19 
11 
 
36 ± 3.1 
23 ± 2.2 
0.659  
17 
13 
 
28 ± 1.71 
11 ± 0.07 
0.010* 
Wound infection 
Present 
Absent  
 
6 
24 
 
11 ± 0.50 
31 ± 1.91 
0.346  
8 
22 
 
18 ± 2.90 
28 ± 2.21 
0.021* 
Sepsis 
Present  
Absent  
 
6 
24 
 
19 ± 2.96 
33 ± 1.71 
0.062  
5 
25 
 
12 ± 2.19 
29 ± 2.33 
0.001* 
Post-op liver 
failure 
Present  
Absent 
 
 
3 
27 
 
 
15 ± 4.6 
23 ± 0.79 
0.792  
 
4 
26 
 
 
12 ± 0.43 
29 ± 2.08 
0.023* 
*p value <0.05 = statistically significant 
 
Table 12: Significant prognostic factors for overall survival by 
multivariate analysis in 30 patients with non-cirrhotic HCC 
Variables 
Hazard 
ratio 
95% CI p-value 
Model 
prediction 
High grade tumors 0.820 (0.694-0.698) 0.019*  
Bilirubin 1.846 (0.893-3.816) 0.098  
Protrombin time 0 .488 (0.117-2.044) 0.327               46.27 
95% CI: 95% confidence interval, *p <0.05 = statistically significant 
 
DISEASE FREE SURVIVAL: 
 Excluding the post-operative death within 30 days, the overall  
1-, 2-, 3- year  disease-free survival rates after curative liver resection 
for HCC in non-cirrhotic patients were 66.6%, 53.3% and 50% 
respectively.  
PROGNOSTIC FACTORS FOR DISEASE-FREE SURVIVAL:  
 Post-operative deaths within 90-days were excluded from the 
analysis of prognostic factors for disease-free survival after liver 
resection for HCC in non-cirrhotic patients. In the univariate analysis, 
need for blood transfusion (p = 0.012), post-operative liver failure  
(p = 0.023), wound infection (p = 0.021), sepsis (p = 0.001), high grade 
tumor(p = 0.001), vascular invasion (0.0001), prothrombin time  
(p = 0.041), serum bilirubin (p = 0.012), post-operative length of stay  
(p = 0.010) significantly affected the disease-free survival (Table-11). 
The multivariate analysis identified high grade tumors (p = 0.039), 
vascular invasion (p = 0.002), and sepsis (p = 0.011) as independent 
prognostic factors for disease free survival (Figure: 7-9) after liver 
resection for non-cirrhotic HCC patients (Table-13). 
Table13: Significant prognostic factors for disease-free survival by 
multivariate analysis in 30 patients with non-cirrhotic HCC 
Variables 
Hazard 
ratio 
95% CI p-value 
Model 
prediction 
High grade tumors 0.092        (0.015-0.590) 0.039*                  
Sepsis  0.091 (0.015-0.574)               0.011 *  
Vascular invasion 0.073       (0.014-0.389) 0.002 *                          
Bilirubin  2.289      (0.129-40.550)             0.572  
Prothrombin time 0 253     (0.033-1.935) 0.185  
Blood transfusion 0.134     (0.006-2.774) 0.194           
Hospital stay               0.981        (0.818-1.176)               0.883                 
Wound infection         0.283        (0.016-5.136)               0.393                        55.70 
Post-op liver failure 0.498 (0.671-2.116) 0.469  
95% CI: 95% confidence interval, *p <0.05 = statistically significant 
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 FIGURE 6: Kaplan-Meier curve showing Overall survival of non-
cirrhotic patients treated for HCC according to tumor differentiation  
FIGURE 7: Kaplan-Meier curve showing Disease-free survival of non-
cirrhotic patients treated for HCC according to tumor differentiation  
 FIGURE 8: Kaplan-Meier curve showing Disease-free survival of non-
cirrhotic patients treated for HCC according to sepsis 
FIGURE 9: Kaplan-Meier curve showing Disease-free survival of non-
cirrhotic patients treated for HCC according to Microvascular invasion 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10: Computerized tomography (CT) scan showing HCC in 
right lobe of non-cirrhotic liver. 
FIGURE 11: CECT showing 
arterial enhancement in HCC. 
FIGURE 12: CECT showing 
early venous washout in HCC. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13: Intra-operative photograph showing 20 x 15 cm HCC 
in right lobe of non-cirrhotic liver 
FIGURE 14: Intra-operative photograph showing dissection of right 
lobe with tumor from inferior vena-cava. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 15: Intra-operative photograph showing line of 
parenchymal transection during right hepatectomy 
FIGURE 16: The resected specimen after right hepatectomy 
  
 
 
 
 
 
 
FIGURE 17: Intra-operative photograph showing 8x6cm HCC in 
left lateral segment of non-cirrhotic liver. 
FIGURE 18: The resected specimen after left lateral segmentectomy 
DISCUSSION 
 
 
 
 
 
 
 
 
DISCUSSION 
 Although most HCC arise in the cirrhotic liver, approximately  
10-40% of cases develop in non-cirrhotic, non-fibrotic liver.
104 
In our 
study, we found that HCC in non-cirrhotic liver represented nearly 39% 
of our resections performed for HCC, thus making it an important 
clinical entity. Many studies have analyzed the outcomes after liver 
resection for HCC, however only few studies have focused solely on 
outcomes after liver resection for HCC in non-cirrhotic, non-fibrotic 
liver. This study analyze a cohort of 30 non-cirrhotic patients who 
underwent liver resection for HCC at Institute of surgical 
gastroenterology and liver transplantation during the period between 
August 2010 and December 2012 with attention paid to clinico-
pathological data and predictors of survival and recurrence. 
DEMOGRAPHIC CHARACTERISTICS: 
 The mean age of HCC in non-cirrhotic patients in our study was 
48.3 years, similar to that reported by Bismuth et al and Chang et al, 
which is about 10 years younger than in cirrhotic patients with HCC. As 
in previous other reports,
26,27,65
  there was a lower male preponderance 
in our study with male: female ratio of 1.7: 1, compared to 4- 8:1 in 
cirrhotic patients.  
 The etiological factors for the development of HCC in non-
cirrhotic HCC are not well documented.
105 
The well-known fact that 
HBV infection has direct carcinogenic potential was supported by a 
small proportion (13%) of patients with HBV infection in our study. 
Although there are few reports
11,26,29,49
  of HCV infection in non-
cirrhotic HCC, there were no such patients in our study. Only 30% of 
our patients are associated alcohol intake, which is concordant with the 
hypothesis that carcinogenic potential of alcohol is almost entirely due 
to development of cirrhosis. In accordance with previous studies (Table 
1-3), the prevalence of three main risk factors for HCC (HBV, HCV and 
alcohol) are low in our study, when compared to cirrhotic patients with 
HCC. There were significant proportion of patients with diabetes 
mellitus (27%) and obesity (10%) in the present study. This finding 
appears to be relevant because many recent reports suggest that diabetes 
and obesity are major risk factors for HCC in non-cirrhotic liver. 
However, in 40% of patients, the etiology was unknown. Such a high 
proportion of non-cirrhotic HCC patients without any identifiable 
etiological factor suggest the possibility of another hitherto unknown 
factor or pathogenic pathway for non-cirrhotic HCC in Indian patients, 
which requires further study. 
 
 CLINICAL PRESENTATION: 
 Due to the absence of underlying liver disease in non-cirrhotic 
patients, HCC is often diagnosed when it has reached a size that 
produces symptoms.
24
 The mean tumor size in our study was 13.2 years, 
which is more than most reported series (<10 cm) (Table-15). This may 
possibly due to delay in diagnosis, referral bias or tolerance and neglect 
of non-specific symptoms by our patients. All the patients in our study 
presented with pain support the view that most of our patients seek 
attention only when tumor has grown sufficient size to produce mass-
related symptoms.    
 It is not surprising to note that the laboratory marker of liver 
function and portal hypertension associated with outcome in cirrhotic 
patients with HCC did not have any significant influence in non-
cirrhotic patients with HCC. This may be partly explained by the poor 
liver function in cirrhotic patients which precludes safe resection. 
Several studies
106
 have proposed that AFP production depends on the 
tumor size or differentiation. In contrast, the AFP level was normal in 
67% of our patients despite the mean tumor size of 13.2cm and 30% of 
patients with poorly differentiated tumors. Moreover, an Indian study by 
Madangopalanet al
107
 has shown the prevalence of AFP in HCC was 
about 51%.      
PERI-OPERATIVE OUTCOME:  
 The site of tumor location, extent of resection was almost similar 
to previous studies, as summarized in table-14. However the operative 
time, blood loss and transfusion requirements were low when compared 
to the older studies. This might be explained by the availability of 
modern technology (Harmonic scalpel, CUSA, waterjet), improved 
surgical skills, advanced anaesthesia and operations performed in highly 
specialized center. Like most other studies (Table-14), none of the peri-
operative parameters were found to be significantly associated with 
outcome after liver resection of non-cirrhotic HCC in the present study.  
Table 14: Comparison ofperi-operative results with previous other 
studies. 
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Bimuth et al
7
 68 61 82 NR NR NR NR 19 2.9 
Shimada et al
29
 65 NR 57 315 1396 NR 30 24.6 0 
Poon et al
12
 155 NR 80 NR 2200 55 NR 39 4.5 
Nagasue et al
10
 100 38 58 148 913 NR 30 22 3 
Grazi et al
11
 135 NR 87 NR NR 25 10 26 3 
Chang et al
9
 223 39 47 NR NR 18 13 31 1.3 
Laurent et al
105
 108 NR 61 NR 750 32 14 23 6.5 
Dupont-Bierre et 
al
4
 
84 54 85 NR NR NR NR 26.2 3.6 
Taura et al
85
 127 NR 38 293 830 38 NR 32 2 
Lang et al
17
 80 42 69 NR NR 0 NR NR 6 
Rayya et al
113
 55 54 74 NR NR NR 18 34 6 
Shrager et al
108
 206 50 72 NR NR 32 NR NR 2.9 
Thelen et al
110
 110 45 61 NR NR NR 15 NR NR 
Our study 30 63 83 165 220 6.7 16 50 3.4 
NR: Not Reported 
 
POST-OPERATIVE COMPLICATIONS: 
  In the present study, one patient (3.4%) died in the post-operative 
period due to post-hepatectomy liver failure following extended right 
hepatectomy. The post-operative morbidity rate in our study (50%) was 
higher than most reported series (19%-39%). The high post-operative 
morbidity in the present study possibly suggests the inevitable 
consequence of the major resections (83%) performed for large tumors 
(mean size: 13.2cm) in non-cirrhotic patients.  
 The most common complication in our study was intra-abdominal 
collection and wound infection followed by sepsis and post-operative 
liver failure. Sepsis was found to be an independent prognostic factor for 
disease-free survival in our study. The reason behind this finding is not 
clear. However, what is clear is that improved survival does not stem 
from the differences in recurrence.  
HISTOPATHOLOGICAL CHRACTERISTICS: 
 The mean tumor size in our study (13.2 cm) was higher than the 
other studies in literature (table-15). Similar to Poon et al
12
 and Shrager 
et al
108
, the positive surgical margin in our study was less (26.7%) in 
comparison with previous studies. However, the multi-nodularity, tumor 
capsule formation, tumor differentiation and vascular invasion were 
similar to most other reported series(table-15). 
Table 15: Comparison of histo-pathological characteristics with 
previous other studies 
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Bimuth et al
7
 68 8.8 12 76 82 NR 46 
Shimada et al
29
 65 5.4 NR 86 63 33.8 50.7 
Poon et al
12
 155 NR 25 45 66 9 45 
Nagasue et al
10
 100 NR 19 71 82 32 38 
Grazi et al
11
 135 7.9 12.6 31.1 39 NR 53.3 
Chang et al
9
 223 7.1 NR 46.2 82.1 47 62 
Laurent et al
105
 108 9.3 20.3 64 49 52 24 
Dupont-Bierre et al
4
 84 8.5 21.4 57 69.6 37.7 39.1 
Taura et al
85
 127 NR 16 NR 63 NR 24 
Lang et al
17
 80 8 21.2 NR 75.7 NR 48.4 
Rayya et al
113
 55 8.2 29 NR 86 NR NR 
Shrager et al
108
 206 8.2 15.5 NR 79.5 9 70 
Thelen et al
110
 110 7.8 30.9 NR 89 NR 39 
Our study 30 13.2 23 63.3 69.7 26.7 50 
NR: Not Reported 
The important negative prognostic factors predicting survival in 
the literature are large tumor size, vascular invasion, positive surgical 
margin, multi-nodularity, tumor differentiation (table-16). In the present 
study, tumor differentiation was found to be independent predictor for 
both poor survival and earlier recurrence whereas vascular invasion was 
significant negative prognostic factor for early recurrence. 
OUTCOMES AND PREDICTIVE FACTORS FOR SURVIVAL 
AND RECURRENCE: 
 Surgical therapy, either liver resection or transplantation, remains 
the gold standard in the curative treatment of HCC. Numerous studies 
have shown that liver resection is the treatment of choice for patients 
with non-cirrhotic HCC. In our study, the overall survival rate of non-
cirrhotic HCC was 86.7%, 66.7% and 63.3% at 1-, 2- and 3-years after 
curative resection respectively, comparable with the results of other 
studies (table-16). It is important to note that such high survival rate and 
cure are achieved only rarely with non-surgical treatment for non-
cirrhotic HCC and even with newer innovative approaches such as SIRT 
(Selective internal radiation therapy), long-term survival is observed 
only exceptionally.
109
 This highlights the pivotal role of liver resection 
in non-cirrhotic patients with HCC and should be aimed for in all 
resectable tumors. 
The disease-free survival after liver resection for non-cirrhotic 
HCC ranges between 31-56% and 24-61% at 3- and 5-year respectively 
in the literature (table-16). 
Table 16: Comparison of survival and recurrence with other 
studies. 
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Bimuth 
et al
7
 
68 59 74 52 40 70 43 33 Size>9cm, 
vascular 
invasion  
Shimada 
et al
29
 
65 NR NR 75 65 NR 56 38 NR 
Poon et 
al
12
 
155 51 80 59 46 57 42 35 NR 
Nagasue 
et al
10
 
100 51 97 76 50 79 38 31 Vascular 
invasion, HCV 
positivity, 
positive surgical 
margin, 
satellitosis, 
major resection 
Grazi et 
al
11
 
135 30 84 68 51 78 58 46 Blood 
transfusion, 
age>60 years 
Chang et 
al
9
 
223 59 NR NR 53 NR N
R 
37 TNM stage 
Laurent 
et al
105
 
108 52 NR 43 29 NR 55 43 Satellitosis, 
absent capsule, 
Blood 
transfusion, 
positive surgical 
margin 
Dupont-
Bierre et 
al
4
 
84 39 78 55 44 73 49 49 Multiple tumors, 
vascular 
invasion, non-
use ofadjuvant 
iodine-131 oil 
Taura et 
al
85
 
127 54 NR NR 81 NR N
R 
N
R 
No independent 
predictors 
Lang et 
al
17
 
80 63 77 38 NR NR N
R 
N
R 
Vascular 
invasion, grade, 
positive surgical 
margin 
Rayya et 
al
113
 
55 73 69 48 48 NR N
R 
N
R 
NR 
Shrager 
et al
108
 
206 52 60 46 NR NR 61 N
R 
Large size, 
satellitosis, 
vascular 
invasion, raised 
AFP 
Thelen et 
al
110
 
110 NR 84 66 50 69 53 42 R1/2 resection, 
growth pattern, 
large & multiple 
tumor 
Our 
study 
30 46.6 86.6 63.3 - 66.
6 
50 - High grade 
tumors, vascular 
invasion, sepsis  
NR: Not Reported, HCV: Hepatitis C virus, TNM: tumor-node-
metastasis stage,  AFP: Alpha-fetoprotein. 
  
In a recent study by Thelenet al
110
 (2013), the disease-free 
survival at 3-year and 5-year was 53% and 42%. Similarly, in the 
present study, the 3-year disease-free survival was 50%.  
 Bismuth et al
7
 has shown a recurrence rate of 59% in non-
cirrhotic patients with HCC during follow-up. Intrahepatic, extra-hepatic 
and both intra & extra-hepatic recurrences were 44%, 15%, 8% 
respectively. Similarly, Dupont-Bierreet al
4
 has found a recurrence rate 
of 41% recurrence after liver resection for non-cirrhotic HCC. The 
intrahepatic, extra-hepatic and both intra & extra-hepatic recurrences 
were 52%, 11%, 37% respectively. The recurrence rate in our study was 
50% and the intrahepatic, extra-hepatic and both intra & extra-hepatic 
recurrences were 38%, 21%, 43% respectively, which is in accordance 
with previous studies. The hypothesis that most early recurrences result 
from metastatic spread rather than de novo origin
111
 was supported by 
the finding that more than 85% recurrences were detected within first 
year. This data highlights the necessity of strict surveillance in the first 2 
years to identify early recurrence after liver resection in non-cirrhotic 
HCC and thereby perform potentially benefitting surgical re-resection.   
 Several prognostic factors that may affect the outcome after liver 
resection for non-cirrhotic HCC were summarized in table-16. Among 
the different predictive factors in different studies, the most constant 
independent predictor for poor survival and early recurrence are large 
tumor size, vascular invasion, positive surgical margin, multi-nodularity, 
tumor differentiation.  
 In the present study, the only independent predictive factor for 
poor survival after liver resection non-cirrhotic HCC in both univariate 
and multivariate analysis was high tumor grade. Similarly, the 
independent predictive factors for early recurrence in both univariate 
and multivariate analysis were high tumor grade, vascular invasion, and 
sepsis. Since vascular infiltration was associated with large tumor size, 
high grade and multifocality in this study, a combination of tumor size, 
grade and number of tumor may be regarded as surrogate marker of 
vascular infiltration.  
To conclude, we noticed a lower male preponderance and lower 
prevalence of main risk factors (HBV, HCV, Alcohol) in patients with 
non-cirrhotic HCC. In spite of delayed presentation and large tumor 
size, major resection can be performed safely in non-cirrhotic HCC 
patients. Vascular invasion, tumor differentiation and sepsis are 
identified as poor prognostic factors after liver resection in patients with 
non-cirrhotic HCC. However, a larger study may be required to confirm 
this hypothesis.  
LIMITATIONS OF THE STUDY: 
1. Small study population 
2. Short period of the study 
In the small cohort of 30 patients with non-cirrhotic HCC, we 
could identify clinic-pathological differences between cirrhotic and non-
cirrhotic patients with HCC as well as assess outcome and prognostic 
factors for survival and recurrence. Moreover, inspite of above 
limitation, the present study lays foundation for future long-term and 
large prospective study.  
CONCLUSION 
 
 
 
 
 
 
 
 
CONCLUSION 
 The present study confirms that HCC can occur in the absence of 
cirrhosis (40%) and without known risk factors (40%). In this setting, 
HCC is more likely to present as large symptomatic mass in a middle-
aged person with lower male preponderance and low prevalence of three 
major risk factors (HBV, HCV and alcohol), when compared to HCC in 
cirrhotic patients.  
 Inspite of large tumor size at presentation, liver resection can be 
performed safely in non-cirrhotic patients with HCC with acceptable 
morbidity and mortality and resection should be attempted whenever 
feasible. 
 This study demonstrated that tumor differentiation (high grade 
tumor) is the only predictor of overall survival in non-cirrhotic patients 
with HCC. Vascular invasion, high grade tumor and sepsis are 
independent predictors of early recurrence in non-cirrhotic HCC 
patients. The presence of these poor prognostic factors in non-cirrhotic 
HCC patients necessitates a stringent follow-up to detect and treat 
recurrence. 
 However, a large sample size and follow-up of this subset of 
patients for 10 or more years could help to confirm the role of vascular 
invasion, tumor differentiation and sepsis as poor prognostic factors and 
identify other factors as long-term prognostic indicators in patients with 
non-cirrhotic HCC. 
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Appendix  
 
 
 
 
 
 
 
 
PROFORMA FOR PROGNOSTIC FACTORS AND 
OUTCOMES AFTER LIVER RESECTION FOR 
HEPATOCELLULAR CARCINOMA IN NON-
CIRRHOTIC, NON-FIBROTIC LIVER 
 
DEMOGRAPHIC DETAILS: 
 
NAME:                                        AGE:                   SEX: M/F                       
 
IP No: 
 
Occupation:                                                                      Income: 
 
Address: 
 
 
Date of Admission:            Date of Surgery:          Date of Discharge: 
 
Length of hospital stay:   Post-op:               Days       Total:            Days 
 
FINAL DIAGNOSIS:                                                 TREATMENT: 
 
 CLINICAL DETAILS:      
Symptoms:  
Abdominal pain/Abdominal distension/Vomiting/ Fever/chills/ 
Jaundice/Loss of appetite/ Weight loss/ Hematemesis/ Melena/ 
Bleeding PR/ Diarrhea/Constipation/ Others: 
Duration:  
Treatment history: RFA/ TACE 
Family history: 
Comorbidities:  DM/ HT/ IHD/ BA/ COPD/Hypothyroid/ others 
Personal History: VEG/ NON-VEG/ SMOKER/ ALCOHOLIC 
 
PHYSICAL FINDINGS:  
PALLOR/ICTERUS/LEFT SUPRACLAVICULAR LN 
                     P/A:         LIVER/GB/MASS PALPABLE/ FREE FLUID 
                     P/R: 
 
PRE-OPERATIVE INVESTIGATIONS: 
Hb%: PCV: TC: DC: P =      /L =       /E =       /M = 
ESR: Platelets: PT: INR: Sugar: 
Urea:  Cr: Na: K: Cl: Ca: 
LFT:  TB:       DB: AST: ALT: GGT: SAP: 
TP: ALB: GLO: HBsAg: HCV: HIV; 
CRP: AFP: CEA: Blood group: Other: 
 
 UPPER GI SCOPY: Date:                     Findings: 
LOWER GI SCOPY: Date:                    Findings: 
USG:   Date:                                Findings: 
CECT abdomen: Date:                              Findings: 
MRI abdomen: Date:                    Findings: 
PRE-OP TISSUE DIAGNOSIS: 
PROVISIONAL DIAGNOSIS:                                                        
PROCEDURE DONE: 
 
INTRA-OP EVENTS: 
             DURATION:                    mins BLOOD LOSS:                  ml 
             TRANSFUSION:            PCV:                  FFP:                   
Platelets: 
             INTRA-OP FLUIDS:                        ml    
             INTRA-OP COMPLICATIONS: 
 
POST OP COURSE:  
POST OP 
EVENT: 
POD Post-op 
Investigation 
POD 
RT removed on:  LFT:  
DT removed on  CRP:  
Urinary catheter:  CBC:  
Oral sips:  RFT:  
Solid diet:  Others:  
 POST OP COMPLICATIONS:                      
INFECTIOUS: Yes/ No Grade: (ClaveinDindo) 
Intra-abdominal 
collection: 
      
Post-op liver failure       
Bile leak/bilioma       
Wound infection:       
Pneumonia:       
Sepsis       
NON INFECTIOUS:   
Bleeding       
Ascites       
Cardiac       
Pulmonary:       
Renal:       
Miscellaneous:       
 
HPE REPORT:   Date:                               No: 
Tumor size:                         Grade:           Stage: T            N            M 
Microvascular invasion: Yes/ No       Macrovascular invasion: Yes/ No 
Capsular invasion: Yes/No                  Margin status: 
Adjoining liver status:  Normal liver/Steatosis/ 
Steatohepatitis/Fibrosis/Cirrhotic 
FOLLOW-UP Details:   Date:                          Last follow-up: 
Duration:                  AFP level:                    
Recurrence:  NO            YES: Intra-hepatic/ Extra-hepatic 
Treatment of recurrence: Re-resection/ RFA/TACE/liver Transplant/ 
Symptomati 
Mortality: Cause                      Date:                     Duration after surgery 
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